Portal Hypertension Market Growth Projections 2023-2032: DelveInsight Analysis | Boehringer Ingelheim, Gilead Sciences, Novartis, Cumberland Pharma, Conatus, Onyx Therapeutics, Inc.

The Key Portal Hypertension Companies in the market include - Boehringer Ingelheim, Galectin Therapeutics Inc., Onyx Therapeutics, Inc., Novartis, Cumberland Pharma, Conatus Pharma, Ferozsons Laboratories Ltd., Histogen, Gilead Sciences, Galectin Therapeutics Inc., and others.

DelveInsight's "Portal Hypertension Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Portal Hypertension, historical and forecasted epidemiology as well as the Portal Hypertension market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Portal Hypertension market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Portal Hypertension Market Forecast [http://delveinsight.com/sample-request/portal-hypertension-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Portal Hypertension Market Report:

*
The Portal Hypertension market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

*
In May 2025, Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company specializing in innovative treatments for metabolic dysfunction-associated steatohepatitis (MASH), today reported encouraging two-year outcomes from the open-label compensated MASH cirrhosis (F4c) cohort of the Phase 3 MAESTRO-NAFLD-1 trial evaluating Rezdiffra. The 122 patients enrolled showed notable improvements from baseline in liver stiffness, liver fat content, fibrosis biomarkers, liver volume, and clinically significant portal hypertension (CSPH) risk scores.

*
Around 2000 Americans per 100,000 have liver cirrhosis in the United States, and more than 90% of those who have cirrhosis go on to develop portal hypertension, according to National Institutes of Health (n.d.)

*
Although it is likely similar to that of the US, the international incidence of portal hypertension is similarly unknown, with variances mostly in the underlying reasons. The major causes of portal hypertension and esophageal varices in Western countries are alcoholic and viral cirrhosis; at the time of diagnosis, gastroesophageal varices are present in 30% of patients with compensated cirrhosis and 60-70% of patients with decompensated cirrhosis

*
Portal hypertension, a disease that precedes the bulk of cirrhotic patients' deaths, eventually develops in about 90% of cirrhotic patients

*
Key Portal Hypertension Companies: Boehringer Ingelheim, Galectin Therapeutics Inc., Onyx Therapeutics, Inc., Novartis, Cumberland Pharma, Conatus Pharma, Ferozsons Laboratories Ltd., Histogen, Gilead Sciences, Galectin Therapeutics Inc., and others

*
Key Portal Hypertension Therapies: BI 685509, GR-MD-02, Sorafenib, Serelaxin, Ifetroban, IDN-6556, Terlipressin, Emricasan, Ambrisentan, belapectin, and others

*
The Portal Hypertension epidemiology based on gender analyzed that portal hypertension affects males slightly more than females

*
The Portal Hypertension market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Portal Hypertension pipeline products will significantly revolutionize the Portal Hypertension market dynamics.

Portal Hypertension Overview

A rise in the pressure inside the portal vein, which conducts blood from the digestive system to the liver, is known as portal hypertension. A obstruction in the blood flow through the liver is the root cause of the rise in pressure. Large veins (varices) grow across the oesophagus and stomach to get past the blockage as a result of increased pressure in the portal vein. The varices deteriorate and become more prone to bleeding.

Get a Free sample for the Portal Hypertension Market Report

https://www.delveinsight.com/report-store/portal-hypertension-market [https://www.delveinsight.com/report-store/portal-hypertension-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Portal Hypertension Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Portal Hypertension Epidemiology Segmentation:

The Portal Hypertension market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

*
Total Prevalence of Portal Hypertension

*
Prevalent Cases of Portal Hypertension by severity

*
Gender-specific Prevalence of Portal Hypertension

*
Diagnosed Cases of Episodic and Chronic Portal Hypertension

Download the report to understand which factors are driving Portal Hypertension epidemiology trends @ Portal Hypertension Epidemiology Forecast [http://delveinsight.com/sample-request/portal-hypertension-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Portal Hypertension Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Portal Hypertension market or expected to get launched during the study period. The analysis covers Portal Hypertension market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Portal Hypertension Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Portal Hypertension Therapies and Key Companies

*
BI 685509: Boehringer Ingelheim

*
GR-MD-02: Galectin Therapeutics Inc.

*
Sorafenib: Onyx Therapeutics, Inc.

*
Serelaxin: Novartis

*
Ifetroban: Cumberland Pharma

*
IDN-6556: Conatus Pharma

*
Terlipressin: Ferozsons Laboratories Ltd.

*
Emricasan: Histogen

*
Ambrisentan: Gilead Sciences

*
belapectin: Galectin Therapeutics Inc.

Discover more about therapies set to grab major Portal Hypertension market share @ Portal Hypertension Treatment Market [http://delveinsight.com/sample-request/portal-hypertension-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Scope of the Portal Hypertension Market Report

*
Study Period: 2019-2032

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Portal Hypertension Companies: Boehringer Ingelheim, Galectin Therapeutics Inc., Onyx Therapeutics, Inc., Novartis, Cumberland Pharma, Conatus Pharma, Ferozsons Laboratories Ltd., Histogen, Gilead Sciences, Galectin Therapeutics Inc., and others

*
Key Portal Hypertension Therapies: BI 685509, GR-MD-02, Sorafenib, Serelaxin, Ifetroban, IDN-6556, Terlipressin, Emricasan, Ambrisentan, belapectin, and others

*
Portal Hypertension Therapeutic Assessment: Portal Hypertension current marketed and Portal Hypertension emerging therapies

*
Portal Hypertension Market Dynamics: Portal Hypertension market drivers and Portal Hypertension market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Portal Hypertension Unmet Needs, KOL's views, Analyst's views, Portal Hypertension Market Access and Reimbursement

To know more about Portal Hypertension companies working in the treatment market, visit @ Portal Hypertension Clinical Trials and Therapeutic Assessment [http://delveinsight.com/sample-request/portal-hypertension-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Portal Hypertension Market Report Introduction

2. Executive Summary for Portal Hypertension

3. SWOT analysis of Portal Hypertension

4. Portal Hypertension Patient Share (%) Overview at a Glance

5. Portal Hypertension Market Overview at a Glance

6. Portal Hypertension Disease Background and Overview

7. Portal Hypertension Epidemiology and Patient Population

8. Country-Specific Patient Population of Portal Hypertension

9. Portal Hypertension Current Treatment and Medical Practices

10. Portal Hypertension Unmet Needs

11. Portal Hypertension Emerging Therapies

12. Portal Hypertension Market Outlook

13. Country-Wise Portal Hypertension Market Analysis (2019-2032)

14. Portal Hypertension Market Access and Reimbursement of Therapies

15. Portal Hypertension Market Drivers

16. Portal Hypertension Market Barriers

17. Portal Hypertension Appendix

18. Portal Hypertension Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=portal-hypertension-market-growth-projections-20232032-delveinsight-analysis-boehringer-ingelheim-gilead-sciences-novartis-cumberland-pharma-conatus-onyx-therapeutics-inc]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.